MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer
Related Experiment Video
Updated: Mar 17, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
You-Jin Lu1, Rong-Yu Liu2, Kun Hu1
1Department of Respiratory Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, Anhui, China.
Abstract:
Lung cancer remains a leading cause of cancer-associated mortality worldwide, and non-small lung cancer (NSCLC) is responsible for over 80 % of lung cancer-related deaths. Identifying novel molecular biomarker that can inhibit the progression of lung cancer will facilitate the development of new treatment strategies. Herein, we demonstrated that miR-541-3p is a tumor-suppressor microRNA (miRNA) in NSCLC progression. We found that expression of miR-541-3p was decreased obviously in NSCLC tissues and plasma. Down-regulation of miR-541-3p was associated with TNM stage and postoperative survival. Overexpression of miR-541-3p inhibited the growth and metastasis of NSCLC cells. The TGIF2 was a direct target of miR-541-3p and promoted the growth and metastasis of NSCLC cells. Further study showed that TGIF2 could reverse the inhibitory effect of miR-541-3p on growth and metastasis of NSCLC cells. Taken together, our data highlight the pivotal role of miR-541-3p in the progression of NSCLC. Thus, miR-541-3p may be a potential prognostic marker and of treatment relevance for NSCLC progression intervention.
Insights
MicroRNA-541-3p (miR-541-3p) acts as a tumor suppressor in non-small cell lung cancer (NSCLC). Lower miR-541-3p levels correlate with advanced NSCLC stages and poorer survival, suggesting its potential as a biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality globally.
- Novel molecular biomarkers are crucial for developing effective NSCLC treatment strategies.
Purpose of the Study:
- To investigate the role of microRNA-541-3p (miR-541-3p) in NSCLC progression.
- To evaluate miR-541-3p as a potential prognostic marker and therapeutic target for NSCLC.
Main Methods:
- Analysis of miR-541-3p expression in NSCLC tissues and plasma.
- Correlation of miR-541-3p levels with clinical parameters (TNM stage, survival).
- In vitro studies assessing the functional impact of miR-541-3p and its target gene (TGIF2) on NSCLC cell behavior.
Main Results:
- miR-541-3p expression was significantly decreased in NSCLC tissues and plasma compared to normal controls.
- Down-regulation of miR-541-3p was associated with advanced TNM stage and reduced postoperative survival.
- Overexpression of miR-541-3p suppressed NSCLC cell growth and metastasis, while TGIF2 was identified as a direct target that reversed these effects.
Conclusions:
- miR-541-3p functions as a tumor suppressor in NSCLC.
- miR-541-3p holds promise as a prognostic biomarker and a potential therapeutic target for NSCLC intervention.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle